Shares of Biogen rose 35% at the market open after the company announced late Tuesday its Alzheimer’s drug, developed with pharmaceutical company Eisai, helped slow cognitive decline in a large phase 3 clinical trial, following a dismal rollout of Biogen’s first Alzheimer’s medication Aduhelm.
